Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
10. Dezember 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.